Supernus Pharmaceuticals (SUPN) Convertible Debt (2013 - 2022)

Supernus Pharmaceuticals (SUPN) has 10 years of Convertible Debt data on file, last reported at $400.4 million in Q1 2022.

• On a quarterly basis, Convertible Debt rose 9.38% year-over-year to $400.4 million in Q1 2022; TTM through Mar 2022 was $400.4 million, a 9.38% increase from a year earlier, with the FY2021 full-year figure at $379.3 million, up 4.84% from the prior year.
• Convertible Debt for Q1 2022 stood at $400.4 million, up from $379.3 million in the prior quarter.
• Over the last five years, Convertible Debt for SUPN reached as high as $400.4 million in Q1 2022 and fell as low as $318.2 million in Q1 2018.
• Historically, Convertible Debt has averaged $350.7 million across 5 years, with a median of $347.2 million in 2019.
• Across the five-year window, Convertible Debt jumped 21769.57% in 2018 and advanced 4.74% in 2019, its largest moves.
• Year by year, Convertible Debt stood at $329.5 million in 2018, then advanced by 4.77% to $345.2 million in 2019, then rose by 4.8% to $361.8 million in 2020, then grew by 4.84% to $379.3 million in 2021, then rose by 5.57% to $400.4 million in 2022.
• Per Business Quant data, the three most recent Convertible Debt figures were $400.4 million in Q1 2022, $379.3 million in Q4 2021, and $374.8 million in Q3 2021.